Otonomy, Inc. Logo
Otonomy Completes Enrollment in Phase 2 Clinical Trial for AuriPro(TM) in Pediatric Patients With Acute Otitis Media With Tympanostomy Tubes
07 mai 2015 07h00 HE | Otonomy, Inc.
SAN DIEGO, May 7, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy to Present at Two Upcoming Investor Conferences
06 mai 2015 07h30 HE | Otonomy, Inc.
SAN DIEGO, May 6, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Appoints George Morrow to Board of Directors
30 avr. 2015 07h30 HE | Otonomy, Inc.
SAN DIEGO, April 30, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Announces FDA Acceptance of AuriPro(TM) New Drug Application
28 avr. 2015 07h00 HE | Otonomy, Inc.
SAN DIEGO, April 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy to Present AuriPro(TM) Phase 3 Results at American Society of Pediatric Otolaryngology Conference
21 avr. 2015 07h30 HE | Otonomy, Inc.
SAN DIEGO, April 21, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Completes Enrollment of OTO-104 Multiple-Dose Safety Study in Meniere's Disease Patients
20 avr. 2015 07h30 HE | Otonomy, Inc.
SAN DIEGO, April 20, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere's Disease
01 déc. 2014 07h00 HE | Otonomy, Inc.
SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy to Present at the Piper Jaffray Healthcare Conference
20 nov. 2014 08h30 HE | Otonomy, Inc.
SAN DIEGO, Nov. 20, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Reports Third Quarter 2014 Financial Results and Provides Corporate Update
12 nov. 2014 16h05 HE | Otonomy, Inc.
SAN DIEGO, Nov. 12, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy, Inc. Logo
Otonomy Enrolls First Meniere's Disease Patients in OTO-104 Multiple-Dose Safety Study
09 oct. 2014 07h30 HE | Otonomy, Inc.
SAN DIEGO, Oct. 9, 2014 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...